China has introduced a groundbreaking vaccine booster, reportedly enhancing immune responses to cancer and infections by up ...

New research led by Yale School of Medicine (YSM) advances the goals of creating a diagnostic test and vaccines for ...

How should continental vaccine manufacturers handle complex dynamics of supply and demand? ANALYSIS | The African Union has ...

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach ...

Everest Medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for EVM14, a Tumor-Associated Antigen (TAA) vaccine.

RNA cancer vaccines are at the forefront of next-generation cancer immunotherapy, showcasing significant potential.

US FDA clears Everest Medicines’ IND application for tumour-associated antigen vaccine, EVM14: Shanghai, China Tuesday, March 25, 2025, 15:00 Hrs [IST] Everest Medicines, a biop ...

The method triggers immune responses that inhibit melanoma, triple-negative breast cancer, lung carcinoma, and ovarian cancer ...

The Company is advancing multiple mRNA therapies targeting cancer and autoimmune diseases, including personalized cancer vaccines (PCVs), tumor-associated antigen (TAA) cancer vaccines ...